1034148-15-6

Basic information

• Product Name: N-[(1R*,2S*)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide
• CAS NO: 1034148-15-6
• Molecular Weight: 460.508
• Mol File: 1034148-15-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-[(1R*,2S*)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1R*,2S*)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide(1034148-15-6)
• EPA Substance Registry System: N-[(1R*,2S*)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide(1034148-15-6)

Safety Data

• Hazardous Substances Data: 1034148-15-6(Hazardous Substances Data)

Upstream product

• 1759-53-1 cyclopropanecarboxylic acid 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 146137-76-0 2-Fluoro-5-iodo-benzaldehyde 
• 1196452-55-7 tert-butyl (1R,2S)-1-hydroxy-1-(6-methoxypyridin-3-yl)propan-2-ylcarbamate 
• 1196452-52-4 [(1S)-2-(6-methoxy-3-pyridinyl)-1-methyl-2-oxoethyl]-carbamic acid t-butyl ester 
• 1025762-98-4 1-(4-fluorophenyl)-5-iodo-1H-indazole 
• 1196452-56-8 (1R,2S)-2-amino-1-(6-methoxypyridin-3-yl)propan-1-ol 

Relevant articles and documents

Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators

A structure-based design approach led to the identification of a novel class of indazole ether based, non-steroidal glucocorticoid receptor (GR) modulators. Several examples were identified that displayed cell potency in the picomolar range, inhibiting LPS-induced TNF-α release by primary peripheral blood mononuclear cells (PBMCs). Additionally, an improved steroid hormone receptor binding selectivity profile, compared to classical steroidal GR agonists, was demonstrated. The indazole ether core tolerated a broad range of substituents allowing for modulation of the physiochemical parameters. A small sub-set of indazole ethers, with pharmacokinetic properties suitable for oral administration, was investigated in a rat antigen-induced joint inflammation model and demonstrated excellent anti-inflammatory efficacy.